Biogen Inc. (BIIB) Earnings Call Transcript & Summary
January 30, 2020
Earnings Call Speaker Segments
Joe Mara
executiveHello, and thanks for joining us on Biogen's call covering results from the fourth quarter of 2019. To get started, please visit the Investors area of biogen.com, where you'll find the earnings release along with the associated financial tables — among them a reconciliation between the GAAP and non-GAAP financial measures we'll be talking about today. Tables 1 and 2 contain our GAAP financials, while Table 3 offers a reconciliation of our GAAP to non-GAAP financial results. In our view, non-GAAP financial results give a truer picture of the continuing economics of our business and show the way we run it internally. We've also put our slides up on our website, and they track the discussions tied to this call. I want to note that forward-looking statements will be made, and these rest on what we currently expect and believe. Such statements carry certain risks and uncertainties, and our actual results could differ materially. For more detail, please review the risk factors covered in our SEC filings. With me on today's call are our Chief Executive Officer, Michel Vounatsos; Dr. Al Sandrock, EVP, Research and Development; and our CFO, Jeff Capello. I'll now hand the call over to Michel.
Michel Vounatsos
executiveHello to all of you, and I appreciate you being here. To begin, I'd like to cover a few key financial results. Biogen ended 2019 with revenue for the quarter totaling $3.7 billion, which was up 4% from the equivalent quarter the previous year. Across all of 2019, Biogen brought in $14.4 billion in revenues, which works out to 7% growth compared with the year before. GAAP earnings for the whole of 2019 came to $31.42 per share, marking a 46% rise over the entirety of 2018. Non-GAAP earnings for all of 2019 reached $33.57 per share, which is a 28% gain relative to the whole of 2018. We feel good about this robust growth over the prior year as we keep carrying out our plan to lead in neuroscience over the long haul. Let me now go through the year. To start, MS revenues for the entire year, which include OCREVUS royalties, came to $9.2 billion, up 2% from the previous year. The count of patients using our MS products around the world rose 3% from the year before, powered by solid patient gains in emerging markets and in every one of the large mature European markets, while our business showed resilience in the U.S. Our team has performed well, showing we can compete in a market that keeps getting more crowded. VUMERITY came to the U.S. market as a notable new option for oral treatment. It's early days for the launch, but so far patients and physicians have shown a level of interest that we're happy with. Turning to SPINRAZA, full-year global revenue reached $2.1 billion, which is 22% higher than the prior year; that blockbuster figure was driven by strong U.S. revenue growth compared with last year, plus even bigger gains outside the U.S., counting the expanded access program and clinical trials, and now over 10,000 patients are on SPINRAZA therapy. As for biosimilars, full-year revenue came to $738 million, a 35% increase year-over-year, largely thanks to IMRALDI. Our estimate is that during 2019, biosimilars we make delivered about EUR 1.8 billion of savings to health care systems throughout Europe, and we expect that amount to continue rising in 2020. That carries real weight as we work to create financial headroom for innovation and boost the long-term sustainability of the health care system; on top of that, we made our biosimilars business stronger during this quarter by signing a new agreement with Samsung Bioepis. Through it, we gain access to 2 new potential ophthalmology biosimilars that represent a substantial market opportunity in major markets around the world, including the U.S. for the first time, as well as commercialization rights in China for our anti-TNFs biosimilars. Fourth, for the R&D organization, this turned out to be a landmark year. The aducanumab results, and what they might mean for patients, doctors, and the broader research world, are something we find encouraging — these are people who've waited many decades for a treatment that could slow Alzheimer's clinical deterioration. Talks are currently underway with the FDA as well as with regulators across Europe and Japan, and our goal is to complete a U.S. regulatory submission as soon as we possibly can. On top of that, the redosing study has moved forward considerably: the protocol has now been filed successfully with the FDA, and at this moment we're working alongside sites and ethics committees to launch that study. Fifth, alongside aducanumab, our pipeline continues to expand and move forward: VUMERITY received U.S. approval, we saw positive data readouts for BIIB059 in lupus, and we brought in 7 additional clinical programs spanning MS, ALS, Parkinson's disease, ophthalmology, and brain contusion. In R&D, 2019 stood out as one of our most productive years on record, and with several potential launches approaching in early 2020, we believe there are many chances to create near-term value. Sixth, we continue generating strong cash flow, which preserves substantial optionality and flexibility for how we allocate capital. Across 2019, cash flow from operations came to about $7.1 billion, an increase of roughly 14% versus the previous year. Throughout the year, we repurchased roughly 24 million shares for about $5.9 billion in total. As we've noted previously, buying back stock is something we see as central to a disciplined approach to allocating capital that builds value. At the same time, we have the financial strength and room to continue evaluating possible outside business development and M&A opportunities. During the past several years, 15 business development transactions have been completed, and they've contributed to major growth in our pipeline. Four deals were closed within the last 3 months alone, including the transaction we've proposed with Pfizer for a possible symptomatic therapy with potential use in both Alzheimer's disease and Parkinson's disease. Like we've said previously, our commitment is to deliver the best possible returns to shareholders even as we continue providing patients with breakthrough treatments — an objective that demands a careful, deliberate strategy for every dollar we invest, whether the payoff comes soon or far down the road. All things considered, Biogen enjoyed a highly productive and triumphant 2019, a year in which we executed on our plan and maintained a steady stream of meaningful achievements. Resilience remained on display throughout our primary MS franchise, which posted gains across both patient counts and revenue, and the introduction of VUMERITY has us energized. SPINRAZA continued its upward trajectory domestically, and the momentum proved even stronger beyond the U.S. borders as our footprint keeps reaching additional markets. SPINRAZA continues to serve as a cornerstone of treatment for SMA, with more than 10,000 individuals receiving the therapy and the most extensive clinical dataset available in this disease. Our biosimilars segment grew, and we broadened both our product offerings and our reach across geographies. At the same time, we are preparing to take a leading role in the battle against Alzheimer's disease, with a U.S. submission planned for aducanumab. In addition to aducanumab, we advanced and enlarged our pipeline, adding 7 new clinical programs and reporting favorable results in lupus. We also produced strong cash flow, keeping our focus on deploying capital strategically so that shareholder return is maximized over the long run. I'll turn things over now to Al, who will provide a more thorough update on what we've recently accomplished in R&D.
Alfred Sandrock
executiveThanks, Michel, and good morning to all of you. First off, I want to extend a welcome back to Dr. Maha Radhakrishnan, who is joining Biogen as our new Chief Medical Officer. Maha's background spans over 16 years, covering numerous geographies and a wide variety of therapeutic areas. She was previously with us at Biogen, serving as Vice President, Europe and Canada, Medical, and Vice President, U.S. Medical, and after that she took on senior medical affairs roles at Bioverativ and Sanofi. As we get ready for upcoming pipeline launches, such as the possible launch of aducanumab, Maha's deep experience is going to be essential. As Michel mentioned, 2019 proved to be a historic year for Biogen. Beyond reporting positive aducanumab results, we achieved meaningful strides in constructing a multifranchise portfolio: we gained approval for VUMERITY, brought in 7 clinical programs, and moved 2 programs forward into Phase III. True to our modality-agnostic strategy, our neuroscience pipeline today encompasses small molecules, antibodies, other advanced biologics, antisense oligonucleotides, and gene therapy. Now let me shift to the progress achieved during the fourth quarter, beginning with Alzheimer's disease and dementia. At last month's Clinical Trials on Alzheimer's Disease, or CTAD, annual meeting in San Diego, we shared top line results from the Phase III studies of aducanumab in early Alzheimer's disease. The final analysis of that data demonstrated that EMERGE was a positive study, with the high-dose regimen of aducanumab reaching statistical significance on both the prespecified primary end point of CDR sum of boxes and all 3 prespecified secondary end points. Conversely, results from the ENGAGE study failed to meet the primary end point. That said, we do believe that data from patients who received sufficient exposure to high-dose aducanumab in ENGAGE reinforce what was found in EMERGE. Please keep in mind that we do not anticipate presenting further aducanumab data ahead of a regulatory decision from the FDA. As Michel noted, with FDA support, we are working to get the open-label aducanumab redosing study started as soon as we can; the protocol has been successfully submitted to the FDA, and we are now collaborating with the sites and ethics committees to get the study underway. In this study, eligible patients who were previously enrolled in our clinical studies, including those who had prior treatment with either aducanumab or placebo, will be titrated to 10 milligrams per kilogram aducanumab infusions every 4 weeks. Alongside aducanumab, we keep advancing a broad Alzheimer's disease portfolio, which includes the Phase III study of BAN2401; BIIB080, a tau-targeted antisense oligonucleotide in Phase I; BIIB076, an anti-tau antibody in Phase I.; and gosuranemab, a distinct anti-tau antibody in Phase II, for which we expect data next year. As we keep building out our Alzheimer's portfolio, our goal is to move into even earlier patient populations to potentially prevent the clinical onset of the disease. With that in mind, our collaboration partner, Eisai, together with the Alzheimer's Clinical Trials Consortium, plans to initiate the AHEAD 3 45 program. The AHEAD 345 program consists of 2 trials, which we call A3 and A45. In the A3 trial, we'll be looking at low-dose BAN2401 against placebo in people who are cognitively normal and who currently fall below the threshold for amyloid positivity, yet face elevated risk of additional amyloid buildup. In the A45 trial, we'll be examining high-dose 240 — BAN2401 against placebo in people who test amyloid positive but have minimal or no cognitive impairment. Taken together, these trials will assess whether giving BAN2401 can slow the buildup of amyloid or the worsening of cognition during the earliest phases of Alzheimer's disease. Now on to MS and neuroimmunology. During this quarter, we're happy to share that the FDA granted approval to VUMERITY, a novel oral fumarate, for treating relapsing forms of MS. Full findings from the Phase II EVOLVE-MS-2 trial, which made a direct comparison of patient-reported GI tolerability between VUMERITY and TECFIDERA, were shared at the European Charcot Foundation Annual Meeting in November and appeared in the journal CNS Drugs earlier this month. On the primary end point specifically, the data demonstrated that those on VUMERITY self-reported 46% fewer days with intensity scores of at least 2 on the individual gastrointestinal symptom and impact scale relative to TECFIDERA. That finding was highly statistically significant, with a p-value of 0.0003. In line with these results, the share of patients discontinuing the study because of GI-adverse events came to 0.8% for VUMERITY and 4.8% for TECFIDERA. Taken together, the data suggest VUMERITY delivers a clinically meaningful gain in GI tolerability relative to TECFIDERA. Throughout our MS portfolio, we keep moving forward BIIB091, an oral BTK inhibitor in Phase I; BIIB061, an oral remyelinating agent in Phase I; and opicinumab, a Phase II anti-lingo antibody for which we anticipate data around the middle of this year. Shifting to our progress in immunology. A tremendous unmet medical need persists for those living with lupus, covering both cutaneous and systemic forms. Treatment choices for lupus remain limited, and new medicines are required to manage this chronic disease that is difficult to treat. Our lupus efforts rest on a long history that Biogen has in immunology, spanning both homegrown assets and collaborations. We were thrilled to report positive data this quarter from the Phase II LILAC study of BIIB059, a potential first-in-class anti-BDCA2 antibody that Biogen discovered and developed, in 2 forms of lupus affecting roughly 800,000 individuals in total across the G7. This 2-part study assessed BIIB059 against placebo in individuals with active cutaneous lupus erythematosus, or CLE, with or without systemic manifestations; and in individuals with systemic lupus erythematosus, or SLE, with active joint and skin manifestations; with a p-value of less than 0.001, the CLE portion of the study hit its primary end point by showing a statistically significant response of BIIB059 on the percentage change from baseline in the CLASI-A score at week 16. Looking at the SLE portion of the trial, it too achieved its primary goal — a decrease in disease activity, which was assessed by measuring the shift from baseline in the combined count of tender and swollen joints at week 24. Within this trial, those receiving 450 milligrams of BIIB059 showed a statistically significant drop of 3.4 in total active joint counts relative to placebo. Beyond that, gains in skin disease and overall disease activity were seen consistently across a number of secondary end points. BIIB059's safety and tolerability profile backs its ongoing development, and our plans involve advancing to Phase III. We feel the BIIB059 program illustrates key aspects of how we broadly approach R&D at Biogen. Take, for instance, how using biomarkers of target engagement alongside an early clinical efficacy measure during clinical development let us produce strong proof-of-biology data and initial proof-of-concept data in Phase I, later verified in a well-controlled Phase II study; we think derisking strategies like these could help raise the odds of success for additional programs throughout our portfolio. Turning to neuromuscular disorders, at last month's International Symposium on ALS Motor Neuron Disease, Biogen, Ionis Pharmaceuticals and our collaborators received the HEALEY Center international prize for innovation in ALS. Given by the ALS Center at Massachusetts General Hospital, this honor acknowledged what we contributed toward discovering and developing tofersen, our antisense oligonucleotide aimed at SOD1-ALS.
Alfred Sandrock
executiveDuring this call, we were happy to share the complete results from the Phase I/II trial of tofersen, and those results showed a statistically significant reduction in CSF SOD1 protein levels, along with trends suggesting a slowing of clinical decline based on 3 separate measures when compared with placebo. On top of that, treatment using tofersen lowered neurofilament levels in plasma as well as in CSF. The consistency we see across the data sets produced in this study encourages us — target engagement, clinical findings, neurofilament findings, and the wide potential for antisense oligonucleotides to go after genetic drivers of neurodegenerative disease. We anticipate data from the Phase III VALOR study of tofersen next year. Beyond that, we kept moving forward with the Phase I studies of BIIB078, an ASO for C9orf72 mediated ALS, and BIIB100, a small molecule inhibitor of XP01 for sporadic ALS. Now switching to ophthalmology: during this quarter, we finished enrollment in the Phase III STAR study of BIIB111 in choroideremia, a rare x-linked inherited retinal disorder that inevitably results in blindness and currently has no approved treatments. Choroideremia impacts roughly 15,000 individuals in the G7 and results from loss of function mutations in the gene-encoding Rab escort protein-1, or REP1. BIIB111 is a gene therapy intended to tackle the underlying cause of this disease by expressing an AAV2-packaged REP1 transgene; in Phase I/II studies, patients given BIIB111 showed a higher rate of maintained vision compared to natural history; moreover, a subset of patients given BIIB111 in Phase I/II studies showed a meaningful improvement in visual activity as defined — sorry, in visual acuity as defined by a gain of at least 15 letters corresponding to 3 lines on the eye chart. To be specific, 21% of patients given BIIB111 showed an improvement of at least 15 letters at 1 year, compared to only 1% seen in the NIGHT natural history study. The Phase I/II studies also showed that BIIB111 was generally well tolerated with an acceptable safety profile; these early signs of efficacy and safety encourage us, and we look forward to data from the Phase III study of BIIB111 toward the end of this year. We are also advancing the Phase II/III study of BIIB112 in XLRP, with data expected in the middle of next year; in stroke, we continue to advance the Phase III study of BIIB093 or IV glibenclamide for cerebral edema caused by large hemispheric infarction, or LHI. In a Phase II study, treatment with BIIB093 was linked to a 46% reduction in midline shift, an imaging measure of cerebral edema, and cut mortality by over 50%. We look forward to data from the Phase III study of BIIB093 in LHI by the end of next year. Additionally, the Phase II study of TMS-007 keeps progressing. TMS-007 is a small molecule modulator of plasminogen that could potentially become a best-in-class thrombolytic drug candidate for patients following an acute ischemic stroke. Data from this study are expected by the end of this year. When it comes to movement disorders, we're still pushing forward with cinpanemab, also known as BIIB054 — that's an anti-alpha-synuclein antibody aimed at Parkinson's disease — and we anticipate Phase II results in the latter half of this year, along with the Phase I trial of BIIB094, an antisense oligonucleotide that targets LRRK2. Last month, we shared top line findings from the Phase II PASSPORT trial of gosuranemab in PSP. The primary end point wasn't achieved, so we halted further development of gosuranemab for PSP and other primary tauopathies. Although this outcome was disappointing, we decided to keep going with the Phase II trial of gosuranemab in early Alzheimer's disease, because the pathophysiology of the disease may differ significantly. Turning to neurocognitive disorders, we kept advancing a Phase II trial of BIIB104, an AMPA receptor potentiator intended for cognitive impairment tied to schizophrenia. Data from that trial are now anticipated in the latter half of this year — of next year. Lastly, it was a productive quarter for business development. Adding more depth in ophthalmology, last month we signed an agreement with Catalyst Biosciences to develop and commercialize Pegylated CB 2782 as a possible treatment for geographic atrophy, or GA. GA is an advanced form of dry age-related macular degeneration, or AMD, that results in blindness, has no approved therapies and impacts roughly 1 million individuals in the U.S. by itself. This molecule is a novel protease that selectively cleaves C3, a genetically validated target in AMD, and we're encouraged by preclinical data showing that one intravitreal injection of this protease removed more than 99% of C3 from the vitreous humor for a minimum of 28 days; additionally, during this quarter, we kicked off a collaboration with CAMP4 Therapeutics to use their gene circuitry platform in hopes of identifying a suite of druggable targets in microglial signaling pathways already understood to play a causal role in neurological disease. And very recently, we announced an agreement to acquire from Pfizer a novel CNS-penetrant small molecule inhibitor of Casein kinase 1, or CK1. CK1 is a key regulator of circadian rhythms, which can become disregulated and contribute to irregular sleep-wake rhythm disorder, or ISWRD, in Parkinson's disease as well as sundowning in Alzheimer's disease. ISWRD is a nonmotor symptom of Parkinson's disease marked by fragmented sleep, severe fatigue and difficulties with activities of daily living. Sundowning affects about 20% of AD patients and causes patients to become confused, anxious and agitated later in the day; in a Phase I study — Phase Ia study, this molecule showed an acceptable safety profile and proof of mechanism. To be specific, there was a statistically significant and dose-related rise in salivary melatonin concentration, a marker of circadian phase modulation. We think this could represent an innovative symptomatic treatment for both AD and PD, and we plan to launch a Phase Ib study by the end of this year. This transaction is subject to customary closing conditions, and we expect it to close in the first quarter of 2020. All in all, Biogen R&D made significant progress in 2019. At this point, we think our situation is a powerful one, with 27 clinical programs: 6 of them in Phase III, 12 in Phase II, and 9 in Phase I, plus a deep preclinical pipeline spanning multiple modalities. Given our intention to submit aducanumab in the U.S., along with several other opportunities coming up soon, we feel no other company occupies as favorable a spot for creating potentially breakthrough medicines for patients who live with devastating neurological diseases. Now I'll hand things over to Jeff.
Jeff Capello
executiveThanks, Al. Good morning, everyone. Now I'd like to go deeper into how we did financially in 2019 and walk you through what we're expecting for 2020. Let's begin with revenues. As Michel said before, Q4 2019 was really strong across each of our main business areas. Fourth-quarter total revenues rose 4% compared with the same period a year earlier, reaching roughly $3.7 billion, while the full year was up 7%, hitting $14.4 billion. All told, our MS business brought in $2.4 billion during the fourth quarter of 2019, which includes OCREVUS royalties of about $205 million. Excluding OCREVUS royalties, MS revenues in Q4 2019 fell 1% against the prior year, but with OCREVUS royalties included, they rose 2%. U.S. MS revenues in the fourth quarter of 2019 got a boost from roughly $135 million more in channel inventory, versus a gain of about $105 million in Q4 2018. Looking at historical patterns, we usually see channel inventory come down in the first quarter after inventory gets built up at year-end. MS revenues for the whole year came to $9.2 billion, with OCREVUS royalties accounting for approximately $688 million of that. Without OCREVUS royalties, full-year MS revenues declined 1% from the prior year, and with them included, they climbed 2%. TECFIDERA revenues worldwide in the fourth quarter totaled $1.2 billion, up 5% from a year earlier. That figure breaks down into $877 million in the U.S., which is 2% higher than Q4 2018, and $284 million outside the U.S., which is 12% above the fourth quarter of 2018. TECFIDERA got a lift from roughly $100 million more in U.S. channel inventory during the fourth quarter of 2019, compared with a gain of about $60 million in Q4 2018. Over the course of 2019, we were happy to observe 4 straight quarters of comparative steadiness in our U.S. share of total prescriptions for TECFIDERA; on top of TECFIDERA's solid results, we introduced VUMERITY in the U.S. late in Q4 and booked $5 million of revenue, every bit of which we credit to channel loading. Beyond the U.S., TECFIDERA once again did very well in the fourth quarter, with robust patient growth across all major European markets and roughly 50% patient growth in Asia Pacific and Latin America compared with the prior year. For the full year, TECFIDERA revenues globally reached $4.4 billion, up 4% from the prior year; that includes $3.3 billion in the U.S. and $1.1 billion from sales outside the U.S. Interferon revenues, which cover both AVONEX and PLEGRIDY, came to $516 million in the fourth quarter, down 14% from Q4 2018 as the shift away from injectable platforms toward oral or high-efficacy therapies continued. That includes $359 million in the U.S. and $157 million from sales outside the U.S. Interferon revenues outside the U.S. took a hit from channel dynamics and the timing of shipments. In the U.S., AVONEX and PLEGRIDY got a boost from roughly $30 million more in channel inventory, versus a gain of about $35 million in Q4 2018. Looking at the whole year, interferon sales globally fell 11%, landing at $2.1 billion — that breaks down as $1.4 billion within the United States plus $675 million from markets abroad. TYSABRI's global revenue came to $473 million during this quarter, which is a 2% gain over the fourth quarter of 2018; the U.S. portion was $270 million while $203 million came from outside the country. Stateside, revenues climbed 5% compared with the same period a year earlier, marking a fourth straight quarter of better year-over-year results. Inside the U.S., TYSABRI inventory held fairly steady, in contrast to roughly $10 million of growth during the fourth quarter of 2018. All through 2019, we were happy to observe that TYSABRI's portion of both new and total prescriptions in the U.S. stayed relatively steady. Beyond the U.S., TYSABRI revenues dropped 2% from the year before, hurt by channel dynamics and shipment timing; across the entire year, TYSABRI's global revenues reached about $1.9 billion, up 2% from the previous year; U.S. revenues came in at $1 billion, with $850 million recorded internationally. On the whole, we felt quite good about how our MS business performed during 2019 and remain focused on keeping this franchise resilient as new competitors arrive in the market. Now let me turn to SPINRAZA. Worldwide SPINRAZA revenues in the fourth quarter totaled $543 million, up 16% from a year earlier and roughly level with the third quarter. Within the U.S., fourth quarter 2019 SPINRAZA revenues were $243 million, rising 3% against both Q4 2018 and Q3 2019. U.S. patient counts on therapy grew 2% from where they stood at the close of 2019's third quarter, with gains driven by both pediatric and adult segments. We keep making solid strides with adults — over 50% of Q4 new starts were adults, and adult growth outpaced our overall patient growth. Keep in mind that adults make up the biggest slice of this market. We've continued to feel an effect from gene therapy among infants, a group accounting for roughly 5% of the entire SMA market. Abroad, fourth quarter 2019 SPINRAZA revenues hit $300 million, a 28% rise over the prior year and a 3% dip from the preceding quarter. Internationally, patient growth was strong across every region, with widespread gains from both established and newly launched countries. The count of commercial SPINRAZA patients rose about 10% compared with 2019's third quarter. Even with that robust patient growth, fourth quarter ex-U.S. SPINRAZA revenues slipped a bit from this year's third quarter, owing to a mix of loading dose dynamics, country mix, shipment timing in certain markets and pricing dynamics. All told, we were once again very happy with SPINRAZA's results this quarter, as patient growth continued across the large, mature markets and uptake stayed strong in emerging markets. On top of that, over half our sales were generated outside America, and we still see a big chance to serve more patients, especially beyond the U.S. Across the whole year, SPINRAZA revenue globally rose 22% to $2.1 billion, powered by a 9% gain in the U.S. to $933 million alongside 34% expansion abroad, reaching $1.2 million. Now let me turn to biosimilars, where we brought in $196 million during this quarter, up 25% from a year earlier; we figure over 200,000 patients are being treated with our 3 anti-TNF biosimilars, roughly a 70% jump compared with the previous year. In Germany, the U.K. and Italy, BENEPALI ranks as the top Enbrel biosimilar. Italy's most prescribed REMICADE biosimilar is FLIXABI; meanwhile IMRALDI holds the lead among HUMIRA biosimilars in key markets including Germany and the U.K. Biosimilars revenue for the full year climbed 35% to $738 million. Moving to anti-CD20, we posted $601 million in the fourth quarter, 12% higher than the prior year, largely on the strength of OCREVUS royalties. Anti-CD20 brought in $2.3 billion for the full year, up 16% against 2018. During the fourth quarter, a RITUXAN biosimilar entered the market for the first time.
Jeff Capello
executiveLooking ahead, we anticipate more biosimilar competition arriving in 2020, and that is likely to create additional strain on RITUXAN sales. And just to remind everyone, the royalty percentage we pay on OCREVUS sales within the United States gets reset annually each calendar year. Other revenues came to $146 million during Q4, which represents a 12% decline from the same period a year earlier, driven by shipment timing. For the entire year, other revenues reached $708 million, up 21% compared with 2018. Keep in mind that other revenues during the first quarter of 2019 got a boost from a sizable one-time Bioverativ shipment. Beyond that, be aware that these revenues fluctuate and are hard to forecast. Now I'd like to discuss gross margin results. For Q4 2019, gross margin stood at 88% of revenues, compared with roughly 86% during the fourth quarter of 2018. This gross margin gain came from somewhat reduced royalties along with decreased costs tied to our revenues. For the whole of 2019, gross margins were around 86%, essentially unchanged from the full year 2018. Turning to Q4 GAAP and non-GAAP R&D expense, that was 19% of revenue, or $692 million. Within Q4 R&D expense, $63 million is tied to the Samsung Bioepis transaction, along with the $45 million opt-in payment made to Ionis for BIIB080 and $30 million connected to our collaboration agreements with CAMP4 Therapeutics and Catalyst Biosciences. For the full year, GAAP and non-GAAP R&D expense came to 16% of revenue, or $2.3 billion. Q4 GAAP SG&A expense represented 18% of revenue, or $665 million. Q4 non-GAAP SG&A expense also represented 18% of revenue, or $662 million. SG&A on both a GAAP and non-GAAP basis rose compared with the previous quarter, mainly because of greater commercial and medical investments, along with the timing of G&A spending. Full year GAAP SG&A was 17% of sales, or $2.4 billion. Full year non-GAAP SG&A was 16% of sales, or $2.3 billion. GAAP other expense, which includes interest, came to $49 million in Q4, while GAAP other income reached $83 million for the full year. Non-GAAP other expense was $50 million in Q4 and $110 million for the full year. What separates these GAAP and non-GAAP figures is mainly gains on strategic investments, which we treat as GAAP only; during both the fourth quarter and the full year, our GAAP and non-GAAP tax rate was about 16%. Relative to the prior year, GAAP and non-GAAP tax rates for both the full year and Q4 of 2019 gained from a nonrecurring shift in the company's tax profile during 2019 and the divestiture of the remaining portion of higher tax inventory in 2018 stemming from intercompany effects. On top of that, the GAAP rate also gained from the unfavorable prior year impact of U.S. tax reform in 2018. Our weighted average diluted share count came in at roughly 178 million for Q4 and 187 million for the full year. During 2019, we bought back around 24 million shares, paying an average of roughly $249 each, for a total of about $5.9 billion. That figure includes some 7.7 million shares repurchased in Q4, worth approximately $2.1 billion. At year-end, roughly $6.3 billion remained available under our repurchase authorization, which takes into account the fresh $5 billion program the Board cleared in December of 2019. That takes us to diluted EPS. For Q4, GAAP earnings per share came in at $8.08, up 71% from the same quarter in 2018, while non-GAAP EPS was $8.34, which is 19% higher than a year earlier. On a full-year basis, GAAP EPS reached $31.42, a 46% gain over 2018, and non-GAAP EPS hit $33.57, up 28% compared with 2018. Net cash flows from operations were about $2 billion in Q4 and roughly $7.1 billion across the full year, which marks the last year in which cash flows are affected by payments to Fumapharm. We closed the quarter holding approximately $5.9 billion in cash and marketable securities along with $6 billion of debt. Now let me move to our guidance for the full year 2020. We're expecting revenues somewhere between approximately $14 billion and $14.3 billion. We project GAAP and non-GAAP R&D expense at 15% to 16% of revenues. For GAAP and non-GAAP SG&A, we're looking at roughly 19.5% to 20.5% of revenue. Our GAAP and non-GAAP tax rates for 2020 should land between 18% and 19%. And for the full year 2020, we anticipate GAAP diluted earnings per share of $29.50 to $31.50, with non-GAAP diluted earnings per share between $31.50 and $33.50. One thing worth noting: this guidance excludes any effect from possible acquisitions or major business development deals, since neither can be easily forecast. The guidance does assume our proposed Pfizer transaction is completed. It also assumes a steady share count based on Q4 of 2019 and no movement in foreign exchange rates. Also important: the guidance assumes there's no generic competition in the U.S. for TECFIDERA during 2020, and it assumes added commercial and R&D costs tied to aducanumab. These projections represent our best current assumptions. As a reminder, we'll give an update at midyear during our Q2 earnings call. I'll hand the call back to Michel now for his closing remarks.
Michel Vounatsos
executiveThanks, Jeff. 2019 was a solid year for us, with every one of our main business segments growing, earnings up by a double-digit percentage compared with the prior year, and excellent execution on every element of our strategy. As we move into 2020, our goal is to keep that momentum going by delivering on our strategic priorities in MS, SMA, biosimilars and our pipeline, with aducanumab at the top of that list. We're getting ready right now for a possible aducanumab launch, starting with the U.S. That means putting a comprehensive go-to-market model in place, bringing on sales staff, expanding our medical teams and getting set for market access; on top of that, we're in active discussions with regulators outside the U.S., such as in Europe and Japan. Our pipeline is advancing beyond aducanumab as well; at this point we have 6 programs in Phase III and 27 clinical programs in total, up from 17 only 3 years back. There are several opportunities for creating value in the near term, spanning Alzheimer's disease, ALS, stroke, lupus, ophthalmology and biosimilars, as our goal is to construct a multifranchise portfolio. From now through the close of 2021, we anticipate 11 mid- to late-stage data readouts, among them Phase III readouts for tofersen in ALS, BIIB111 in choroideremia and BIIB093 in large hemispheric infraction, plus 8 Phase II readouts spanning MS, Alzheimer's disease, Parkinson's disease, ophthalmology, schizophrenia, acute neurology and neuropathic pain. As the neuroscience leader with asymmetric core capabilities, we're confident that no other company is in a stronger position to keep delivering breakthrough therapies for nervous system diseases, meeting a substantial and expanding unmet medical need. We'll keep carrying out our core strategy of building the multifranchise portfolio across our core and emerging growth areas. Let me restate our dedication to maximizing shareholder returns and delivering innovative therapies to patients over the long run. That requires us to keep examining capital in an efficient, effective and appropriate manner. As we've shown before, we will always work toward an optimal capital structure and pursue superior returns on the investments we make. I'd like to spend a moment on our wider purpose as an organization, since we seek to pioneer science for the betterment of humanity. That covers doing what's right for patients, for our employees, for the environment and for the community, and we believe all of it adds to long-term sustainable shareholder value. What Biogen represents makes me proud, and I believe this approach puts us in a good position to be a sustainable organization over the long term, as we stay focused on leading in neuroscience to address the enormous societal needs in this area. Last, I want to thank our employees worldwide, who are devoted to making a positive difference in patients' lives, along with all the physicians, caregivers and participants in our clinical development programs. Their passion and commitment are what make our past and future achievements possible. We'll now open the call for questions.
Geoff Porges
analystNice work on the quarter, the results, and all the strides you've made. Jeff, just a few quick questions about the guidance. Could you describe which assumptions you've factored into that guidance regarding how the imminent Risdiplam launch might affect SPINRAZA? And separately, have you included the complete launch costs for aducanumab? Your sales force and all of that — you touched on it — but is it fully accounted for within that guidance?
Jeff Capello
executiveThanks for those questions, Geoff. Regarding Risdiplam, our assumption is that the product does indeed launch. So, like everyone else, we expect to sort of look at the data and sort of what it signifies. We should remind everyone that 10,000 people are on therapy today, responding very well, with discontinuation rates that are very low. So we'll sort of watch what the data shows and how that product gets received. Still, there's certainly plenty of growth opportunity awaiting us. As for aducanumab, we won't offer a specific view on numbers when it comes to the launch. Instead, I'd simply direct you back to the SG&A guidance, which has risen considerably on a percentage basis, and from that you can gauge how much more we're spending year-over-year compared with what we spent last year. And I believe that's the prudent approach, considering the significant opportunity in front of us, which has us quite excited.
Terence Flynn
analystI might just ask 2 things. I was curious whether you could share additional specifics regarding what is holding up the aducanumab submission. Also, do you anticipate that it will receive a priority review? Then, what's the expectation when it comes to regulatory submissions outside the U.S.? Is your confidence in submitting in Europe and Japan comparable to what you have for the U.S.?
Alfred Sandrock
executiveTerence, it's Al here. Essentially, what's involved is compiling the paperwork — the electronic common technical document, which is a digital file containing hyperlinks and so forth; the task is pulling all of that together and sending it in to the FDA. As for how we've been interacting with them, we've had discussions going back to last — the initial Type C meeting occurred last June, and those have proven quite productive. It's — never in my experience — for me this is an unprecedented scenario. I believe it's fairly uncommon throughout the industry. Still, I'd say that there has been — a substantial degree of productive dialogue has existed since last June. Regarding the remaining geographies, our conversations with them have begun, though it remains early; and — even so, we do expect that we'll be submitting in those other geographies too at some point.
Ronny Gal
analystNice work on the quarter. You mentioned that a redosing study is getting underway. Could you walk us through what you hope that study will achieve? Since a protocol is now in place, what are the endpoints, and what kind of data should we anticipate? Also, on VUMERITY, can you give us some color on the launch strategy? My understanding is that it hasn't yet taken a real commercial step. Could you speak to whether you intend to apply the same parity business model used for TECFIDERA? Or are there particular aspects of VUMERITY — regarding patient access, assistance programs, and similar matters — that will come out ahead of or behind TECFIDERA?
Alfred Sandrock
executiveRonny, Al here. The primary motivation for conducting the redosing trial was compassionate in nature. We had a group of participants who had willingly enrolled in our clinical research. Their involvement made it possible for us to develop aducanumab. We believed we had an obligation to give back to them. A number of these individuals had expressed to the investigators a desire to receive the medication. That is the principal rationale. As I mentioned earlier — in the comments I prepared — this is essentially a study with only one treatment arm. Each participant is dose-escalated to 10 milligrams per kilogram of aducanumab. Everyone who took part in earlier trials, even those who received placebo, can join. When you have a study with only one arm, safety and tolerability are essentially the only things you're able to assess, and our plan from the beginning was to run a long-term extension—we actually already had one set up for looking at safety and tolerability over an extended period. That's why those measures serve as the study's primary end point. Beyond that, naturally, we'll also examine efficacy to whatever degree is possible in a single-arm design, since we'd want to know whether any benefit holds up over time. Naturally, we'll be examining amyloid alongside other biomarkers, and we'll also determine if the treatment gap influenced those types of markers in any way.
Michel Vounatsos
executiveRegarding the latter portion of your inquiry, Ronny: because VUMERITY offers better GI tolerability, we see a chance to reinforce the entire fumarate lineup. That said, TECFIDERA stays at the heart of what we promote — you can observe how it's performing, and we'll keep backing it. Also, boosting this fumarate's share later on will be an important measure; we're happy with the access secured so far, which beats what we witnessed from rivals a few months post-launch, and for one competitor, 12 months post-launch. So the access pleases us. We track the stat forms and the grads very carefully. It's good to see thus far that more stat forms are being written ex-TEC than TEC. So that's — yet we're only at the start. It's somewhat too soon; once we have additional data, we'll return with greater detail.
Phil Nadeau
analystI'd like to ask about TECFIDERA and its intellectual property. As I understand it, a decision on the IPR is expected next week. If the IP were invalidated, could you explain the sequence of events that would follow and how the appeal process would unfold? And what's the current status of the court case? Assuming the IPR goes your way next week, could you give us an update on timing?
Jeff Capello
executiveSure, Jeff here. On the IPR side, we should get a decision no later than the end of the first week of February, which would make it the first of the 3 rulings. If we win, great, whatever it says. If we lose, we plan to appeal, and that typically takes 12 to 18 months. There are 2 other matters, in West Virginia and Delaware, that should be resolved around midyear, plus or minus a month or 2. Winning those would be great. If we don't, we'll appeal all of them, and that appeal period also generally runs 12 to 18 months. Obviously, we're awaiting those decisions. We believe our patents are valid. That said, these outcomes are difficult to predict. There are many considerations. There are multiple rulings, as we just covered, plus the appeal timelines. Then you have to factor in whether a launch at risk would occur if we don't prevail. Near-term forecasting is challenging, so we'll keep everyone updated on how things develop as the year goes on. We're also seeing 30% growth outside the US to $1.2 billion.
Umer Raffat
analystAl, if I could, I'd like to spend a moment expanding on the Alzheimer's topic. It's quite evident that the FDA has a lengthy track record of granting approval to CNS medications that had unsuccessful or negative trials previously. Nevertheless, whenever the FDA moves in that direction, what I observe is that they combine data from absolutely everything; so what I'm asking is, were you to combine the data from ENGAGE, EMERGE, and Phase Ib, what would the picture be? It would be quite useful to grasp that. Additionally, how many post-hoc analyses took place prior to your team reaching the Protocol Version 4 population? My main reason for asking is that I'm attempting to figure out how we ought to consider what the p-value should be in light of all the splits that in theory ought to be considered before we got to PV 4?
Alfred Sandrock
executiveSo Umer — I mean apologies, Umer, this is Al Sandrock speaking. I — we have not revealed findings from any other types of analyses, pooling or subsets included. Therefore, we won't be doing so this morning; however, what I would say is that — I would not presume that — I mean, when you examine the past record of drugs that got approved, I wouldn't claim that pooling is invariably what happens. I believe there are cases that don't follow that, so I would not presume that applies here. And let me think, your question — the other thing you asked was, how many post-hoc analyses, we did state it was post hoc, but the number of them escapes my memory.
Geoff Meacham
analystI've got just a handful of things. Regarding SMA and clinical development, there are patients who went from ZOLGENSMA back to SPINRAZA. I'm just wondering whether you've observed proof that this happens in actual practice? Then, Al, a broader question about Alzheimer's. So if I take it as given that an Abeta antibody serves as an anchor therapy, when we consider combination strategies further out, is there essentially a rapid route to reduce risk? Put differently, do you believe the FDA — you could initially examine surrogate markers like PET imaging, and afterward, further out, examine cognition? I'm only trying to get a feel for how things look following aducanumab?
Alfred Sandrock
executiveYes. On the SMA and ZOLGENSMA topic you raised first: honestly, calling it a switch back doesn't quite fit how I see it, because once someone has gotten ZOLGENSMA, there's a reasonable case that they're still on it, in a sense. The gene therapy's benefits are still working for them. So in some ways it looks like adding SPINRAZA on top, which is something we've heard about and which does happen in real-world care. Why would families and doctors choose that route? My sense is they feel there may still be room for further improvement, and that matches what I hear from actual practice. On that data, we're starting to collect it, though we don't have conclusions yet. Since it's happening in real practice and we care a lot about real-world evidence, we've begun gathering it. As for Alzheimer's combination approaches, one reason we structured the pipeline this way is that combination therapy was always in our vision. The most obvious first partner for aducanumab or BIIB2401 would be something targeting tau, like an anti-tau agent or a tau ASO. That said, it was a nice surprise to find aducanumab already has an effect on tau, so that's something to remember. Still, the clearest path forward, in my view, is pairing it with tau as the following move. It's also possible that particular phases of the illness benefit from that pairing more than others do. As for accelerated approval, yes, biomarkers will be part of our approach — not just for the harmful proteins we aim to lower, Abeta and tau, but perhaps for additional biomarker types that capture additive effects more quickly. That said, in the end I expect we'll still have to demonstrate that the combination slows clinical decline to a greater degree; that point will likely remain essential. Unless it simply can't be done. To phrase that another way, suppose someone is at an early Alzheimer's stage with no cognitive impairment — in that situation, the test might not work for them, and biomarkers by themselves could be the sole method available.
Michael Yee
analystYou mentioned some things about getting ready for aducanumab, SG&A included. Can you give us a bit more detail on, I suppose, the effort underway regarding the timeline for when the sales force will actually be active? And perhaps a few thoughts on what payers are telling you, and how they're framing their view of this kind of drug? And what sort of access such a drug would receive? Then a fast one as well about Al. A DIAN-TU study is reading out. I'm certain folks will attempt to draw read-throughs regarding what that implies for the beta amyloid here? Maybe just a remark on anything worth knowing, or your take on that trial.
Michel Vounatsos
executiveSo Michael, let me begin with launch readiness if I may. In fact, this effort began over 2 years back, with a grasp of the patient journey, from origination to diagnosis, the referral dynamics that shifted market to market, and even inside the U.S., which differs, grasp the various kinds of market inside the U.S., it's the various segments. We have examined the go-to-market for the U.S. This has been approved and this is funded in our budget, as discussed. And the hiring has begun, first with the medical affairs, obviously. Engagement with scientific leaders, also at the community level matters; and also the biomanufacturing must be ramped up and be prepared for potentially greater demand with the functional support, okay? To support the greater engagement and team. Regarding price, it's still early, even if we are making progress. We engage with stakeholders because, as you can imagine, there is nearly no drug cost today. So we engage with patient association, pharmacoeconomics, therapeutics and all the customers, mostly in the U.S. and outside the U.S. Past the price, it's all about the access condition and the affordability. We know that the longer we wait, the more transition — people will transition to full-blown assistance and loss of dependence, which costs society so much. So essentially, we start engaging; and hopefully, we'll have all the incentives in that field in order to further invest in R&D. This is our belief; so good progress, step-by-step, but we engage broadly and we ask for advice and we listen.
Alfred Sandrock
executiveAl here, Michael. So DIAN-TU — DIAN being the dominantly inherited Alzheimer's network. Clearly, for these patients, amyloid is probably causal, since the majority of dominantly inherited mutations causing primarily Alzheimer's disease occur in APP, which is the amyloid precursor protein, or in the enzymes that process it. So I find these studies quite interesting. From what I understand, the two drugs under investigation are solanezumab and gantenerumab. Should the results come out positive, I believe that would provide additional backing for the amyloid hypothesis. Should they come out negative, I would need to observe evidence of target engagement along with biological changes in the brain prior to drawing any conclusions.
Cory Kasimov
analystI'd like to raise a question about capital allocation. With the portfolio and pipeline the company has right now, and taking into account how the market is behaving, how do you weigh the relative appeal of buying back more stock — you've got more than $6 billion of dry powder sitting there — against opportunities in business development? I suppose what I'm really asking is whether you have enough bandwidth to pursue both in a meaningful way. And on the acquisition side, how much of an appetite do you currently have?
Jeff Capello
executiveCory, this is Jeff, and I appreciate the question. From that standpoint, we're sitting in a good spot, correct? At the close of the year, we carried no net debt. Cash flow of $7 billion was generated by us in 2019, and we anticipate another strong year for cash flow in 2020. That gives us the financial flexibility to pursue both, and pursuing both is what we've been doing. Across the last 3 years, 15 M&A BD-type transaction were completed by us, with $3.5 billion spent. And during the last year alone, 24 million shares were bought back for nearly $6 billion. So when it comes to building the pipeline, our interest is strong. The pipeline has gone from 17 clinical assets to 27 — a significant increase. Among those 27, 11 have important readouts over the next 2 years, and 5 of them could have a meaningful impact on the company. So our feeling about that is good. Adding to those assets and building the pipeline further is something we'd like to keep doing. At the same time, though, $6.3 billion of authorized share repurchase capability is also available to us. So good decisions that serve the best interest of the shareholders over the long term will keep being made by us, and the capacity to do both will be there.
Matthew Harrison
analystI've got a question for Al regarding two programs in the pipeline. Al, could you explain what might set a LRRK2 ASO apart from the kinase inhibitors we've observed being developed? After that, perhaps you could give your perspective on anti-LINGO-1 for MS? Has anything shifted since that trial was started? Or is there any fresh information on it?
Alfred Sandrock
executiveWe think LRRK2 is a great target for Parkinson's disease — not just for patients who have familial PD caused by LRRK2 mutations, but possibly for sporadic Parkinson's disease too. As for the ASO, it's a different way to go — rather than blocking the enzyme using a small molecule, you lower how much LRRK2 is present, and whether that works is still unknown. One point about the ASO: since we administer it intrathecally at CNS, its effect on LRRK2 will be limited to the central nervous system, while a small molecule could act on the enzyme elsewhere; apart from that, though, it's still early to tell whether these drugs will work. Regarding anti-LINGO, the Phase II trial we're running now differs from the initial Phase II trial because we picked patients using advanced imaging to confirm they truly had demyelination according to MTR and truly had intact axons according to DTI; we also picked the dose that appeared most promising from that first Phase II trial. And we're pairing it with several distinct immunomodulators. In that initial trial, we paired it only with interferon, but at present we're pairing it with TECFIDERA and TYSABRI along with interferon, to determine whether the amount of inflammatory disease in the brain influences remyelination. Maybe with less inflammation, the oligodendrocyte precursor cells can remyelinate more effectively; that's what's different, and we'll learn soon whether the second trial turns out positive.
Jay Olson
analystCongratulations on a strong 2019. Can you say more about why you're looking at BAN2401 in people with amyloid levels under the positivity cutoff? Also, is the aim to establish a complementary role for BAN2401 in patient groups that would differ from aducanumab?
Alfred Sandrock
executiveWell, we do see this — we see the 2 drugs as belonging to a multidrug franchise, and we'll deploy the drugs in the places they naturally suit best, and data will be required for that. The fact that someone isn't positive on a visual read doesn't mean no amyloid buildup is happening. So I think that's a key distinction. And in certain respects, the A345 study examines — across the 2 studies, examines both Stage 1 and Stage 2, both of the — both stages as defined in the FDA guidance document released last year covering the various stages of Alzheimer's disease. So I'd say those 2 studies assess both Stage 1 and Stage 2, and I believe both are important to study.
Joe Mara
executiveThere's probably time for 2 more questions.
Evan Seigerman
analystNice work on the quarter. Turning to next week and what the IPR might produce — suppose things don't break your way. Would you rethink where business development sits relative to buybacks, or does that have to wait until you get the rulings in those court cases around midyear?
Michel Vounatsos
executiveAppreciate that question. Our view is that BD and M&A chances stand on their own, separate from whatever comes next week or whatever took place 6 months back, in March. We stay — we're heavily involved in BD possibilities, and the team keeps evaluating ways to build shareholder value; none of that depends on any outcome.
Jeff Capello
executiveYeah. And only to remind everyone, we closed out the year with zero net debt. Plus, during 2019, our cash flow came to $7 billion. So doing both is something we have the ability to handle.
Robyn Karnauskas
analystTo put investors at ease somewhat, when we consider Alzheimer's, if it gets approved, since you're administering a very large quantity of antibody — could you offer reassurance regarding cost of goods and margins, so it wouldn't prove too damaging? I realize your manufacturing capacity is quite strong, but that still amounts to a great deal of antibodies. So at what point would we find that out? And could you reassure us that the sum required to manufacture this drug isn't so enormous that it would strain the system excessively?
Jeff Capello
executiveYes. Thank you for raising that; clearly this is something we've been examining for some time. All I can say is that I'd rather not dive into excessive detail on that matter right now, but we take comfort in knowing that because of the characteristics of the substance we'll make, the margin will be reasonable, and it will perform well from an economic standpoint.
Joe Mara
executiveSo I'm going to turn it back over to Michel for his closing comments.
Michel Vounatsos
executiveThanks, everyone, for joining this call. We've closed the book on an exceptionally robust 2019, and at this point the Biogen team stands prepared for a highly consequential 2020 — and clearly, one key focus being a possible aducanumab. I appreciate your time.
Joe Mara
executiveThank you. End the call.
Operator
operatorThank you again for joining today's conference. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.